These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11483671)

  • 1. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.
    Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J
    J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective.
    Meta J; Seltzer M; Schiepers C; Silverman DH; Ariannejad M; Gambhir SS; Phelps ME; Valk P; Czernin J
    J Nucl Med; 2001 Apr; 42(4):586-90. PubMed ID: 11337546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective.
    Yap CS; Seltzer MA; Schiepers C; Gambhir SS; Rao J; Phelps ME; Valk PE; Czernin J
    J Nucl Med; 2001 Sep; 42(9):1334-7. PubMed ID: 11535721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of PET on the management of lung cancer: the referring physician's perspective.
    Seltzer MA; Yap CS; Silverman DH; Meta J; Schiepers C; Phelps ME; Gambhir SS; Rao J; Valk PE; Czernin J
    J Nucl Med; 2002 Jun; 43(6):752-6. PubMed ID: 12050318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
    Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET in the management of lymphoma: a clinical perspective.
    Hoskin PJ
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
    [No Abstract]   [Full Text] [Related]  

  • 8. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodal staging of lymphoma with whole-body PET: comparison of.
    Sutinen E; Jyrkkiö S; Varpula M; Lindholm P; Grönroos T; Lehikoinen P; Teräs M; Minn H
    J Nucl Med; 2000 Dec; 41(12):1980-8. PubMed ID: 11138682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.
    Dizendorf EV; Baumert BG; von Schulthess GK; Lütolf UM; Steinert HC
    J Nucl Med; 2003 Jan; 44(1):24-9. PubMed ID: 12515872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
    Schiepers C; Filmont JE; Czernin J
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
    Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
    J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
    Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U
    Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
    Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.